Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
A phase I study of enzastaurin (ENZ), an oral PKC inhibitor, in combination with erlotinib (ERL) administered orally daily to patients with advanced solid malignancies Wakelee, H. A., Padda, S. K., Chhatwani, L., Pedro-Salcedo, M., Krupitskaya, Y., Musib, L., Latz, J. E. PERGAMON-ELSEVIER SCIENCE LTD. 2008: 126
View details for DOI 10.1016/S1359-6349(08)72335-8
View details for Web of Science ID 000261221200400